Synthetic Genomics, Avoca Ink Deal for Natural Astaxanthin | GenomeWeb

NEW YORK (GenomeWeb) – Avoca and Synthetic Genomics today announced a supply agreement to extract and commercialize natural astaxanthin from algae strains developed by SGI.

The agreement also gives Avoca the exclusive rights to sell in North America products based on SGI-produced astaxanthin. Avoca's parent firm, Pharmachem Laboratories, will market and sell the products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.